Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Receivables - Other (2019 - 2021)

Historic Receivables - Other for Keros Therapeutics (KROS) over the last 3 years, with Q2 2021 value amounting to $100000.0.

  • Keros Therapeutics' Receivables - Other changed N/A to $100000.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $100000.0, marking a year-over-year change of. This contributed to the annual value of $900000.0 for FY2019, which is N/A changed from last year.
  • Keros Therapeutics' Receivables - Other amounted to $100000.0 in Q2 2021.
  • In the past 5 years, Keros Therapeutics' Receivables - Other ranged from a high of $900000.0 in Q4 2019 and a low of $100000.0 during Q2 2021
  • Moreover, its 3-year median value for Receivables - Other was $805000.0 (2020), whereas its average is $601666.7.